Celera Corporation Says Case-Control Publication on KIF6 Does Not Refute Prior Research on KIF6’s Association with Coronary Heart Disease and Statin Benefit

ALAMEDA, Calif.--(BUSINESS WIRE)--Celera Corporation (NASDAQ:CRA) today noted that the case-control studies describing a lack of association between KIF6 and coronary artery disease (CAD) published in the Journal of the American College of Cardiology did not investigate the association between KIF6 and statin benefit and the results are subject to fundamental biases that limit any comparison to the previous prospective studies that found an association between KIF6 and coronary heart disease (CHD).